MetaCap

Neuronetics Inc. (STIM)

NASDAQ: STIMHealth CareMedical/Dental InstrumentsUSD

1.25+0.01 (+0.81%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

STIM stock chart

Technical analysis

Key statistics

All statistics
Market cap
$120.60M
EPS (TTM)
-$0.32
52-week range
0.80 – 3.44
Day range
1.12 – 1.26
Volume / Avg
2.99M / 1.76M
Beta
—

52-week range

$0.80$3.44

STIM stock today

Neuronetics (STIM) closed at $1.25 on Nov 20, up 0.81% (+$0.01), versus the S&P 500's 3.70% decline. Shares are 63.7% below their 52-week high of $3.44, set on Aug 11, 2026 and 56.2% above the 52-week low of $0.80, near the bottom of the past year's range. STIM is down 9.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 4.6%.

Neuronetics has posted a net loss over the last twelve months (EPS of -$0.32), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Neuronetics

Company profile

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

Industry
Medical/Dental Instruments
CEO
Mr. Daniel L. Reuvers
Headquarters
Malvern, PA
Employees
658
IPO year
2018

Financial highlights

Full financials

In fiscal 2025, Neuronetics generated $149.2 million in revenue, up 99.2% from fiscal 2024, its 5th consecutive year of revenue growth. Neuronetics reported a net loss of $39.0 million, compared with a loss of $43.7 million a year earlier. Gross margin was 48.5% (down from 72.3%) and operating margin -21.1%.

Neuronetics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$149.16M$74.89M$71.35M$65.21M$55.31M
Growth+99.17%+4.96%+9.42%+17.89%+12.32%
Net income$-39.00M$-43.71M$-30.19M$-37.16M$-31.19M
EPS (diluted)$-0.59$-1.38$-1.05$-1.38$-1.22

Analyst forecast

Forecast

Consensus (4 analysts)

strong_buy

Avg. price target

$6.00+380.00%

  • Strong buy 1
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $5.00High $7.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.13 vs $-0.08
Surprise
-62.50%

STIM news

All STIM news

Neuronetics peers

Health Care sector
STIM peer companies
CompanyPrice% ChgMarket capCompare
LUNGPulmonx Corporation2.57-6.20%$111.93Mvs STIM
PYPDPolyPid Ltd.6.12-6.56%$129.29Mvs STIM
APYXApyx Medical Corporation2.40+0.42%$101.10Mvs STIM
KRMDKORU Medical Systems Inc.3.19-7.27%$138.37Mvs STIM
NYXHNyxoah SA0.805-7.01%$81.98Mvs STIM
SKINSkinHealth Systems Inc. Class A11.77-3.13%$76.68Mvs STIM
LUCDLucid Diagnostics Inc.0.3727-3.52%$72.57Mvs STIM
QTEXQTREX Quantum Ltd.1.00-10.71%$70.63Mvs STIM

Indexes, lists and sector

Neuronetics stock FAQ

What is Neuronetics's stock price today?

STIM last traded at $1.25 as of Nov 20, 4:00 PM EST, up 0.81% on the day. Prices are delayed at least 15 minutes.

Who is Neuronetics's CEO?

Mr. Daniel L. Reuvers is the chief executive officer of Neuronetics Inc., which has about 658 employees.

What is the STIM 52-week high?

The 52-week high for STIM is $3.44 and the 52-week low is $0.80. The stock is currently 63.7% below its high.

Compare STIM